Rivoceranib

Rivoceranib is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. Additionally, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include rivoceranibum and Apatinib. Its PubChem CID is 11315474.

CAS No 811803-05-1
Molecular Formula C24H23N5O
Molecular Weight 397.5 g/mol
Synonyms N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide

Frequently Asked Questions